These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38959505)

  • 1. Barriers to, and Facilitators of, Checking Drugs for Adulterants in the Era of Fentanyl and Xylazine: Qualitative Study.
    Aronson ID; Ardouin-Guerrier MA; Baus JE; Bennett AS
    JMIR Form Res; 2024 Jul; 8():e56755. PubMed ID: 38959505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating Technologies to Identify Fentanyl and Adulterants in Street Drug Paraphernalia: Qualitative Perspectives of Service Providers and Their Clientele.
    Santelices C; Matsumoto A; Boulad M; Stopka TJ
    Subst Use Misuse; 2023; 58(12):1528-1535. PubMed ID: 37424449
    [No Abstract]   [Full Text] [Related]  

  • 3. Recommendations from people who use drugs in Philadelphia, PA about structuring point-of-care drug checking.
    Reed MK; Borne E; Esteves Camacho T; Kelly M; Rising KL
    Harm Reduct J; 2024 Jan; 21(1):26. PubMed ID: 38287409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug checking as a potential strategic overdose response in the fentanyl era.
    Laing MK; Tupper KW; Fairbairn N
    Int J Drug Policy; 2018 Dec; 62():59-66. PubMed ID: 30359874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "If I had them, I would use them every time": Perspectives on fentanyl test strip use from people who use drugs.
    Reed MK; Salcedo VJ; Guth A; Rising KL
    J Subst Abuse Treat; 2022 Sep; 140():108790. PubMed ID: 35577663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive testing and rapid dissemination of local drug supply surveillance data in Rhode Island.
    Collins AB; Wightman RS; Macon EC; Guan Y; Shihipar A; Krieger M; Elmaleh R; Smith MC; Morales A; Badea A
    Int J Drug Policy; 2023 Aug; 118():104118. PubMed ID: 37422985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substance use patterns, sociodemographics, and health profiles of harm reduction service recipients in Burlington, Vermont.
    Erath TG; LaCroix R; O'Keefe E; Higgins ST; Rawson RA
    Harm Reduct J; 2024 Apr; 21(1):76. PubMed ID: 38580997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xylazine detected in unregulated opioids and drug administration equipment in Toronto, Canada: clinical and social implications.
    Bowles JM; McDonald K; Maghsoudi N; Thompson H; Stefan C; Beriault DR; Delaney S; Wong E; Werb D
    Harm Reduct J; 2021 Oct; 18(1):104. PubMed ID: 34645480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How do we understand the value of drug checking as a component of harm reduction services? A qualitative exploration of client and provider perspectives.
    Moran L; Ondocsin J; Outram S; Ciccarone D; Werb D; Holm N; Arnold EA
    Harm Reduct J; 2024 May; 21(1):92. PubMed ID: 38734643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adulterants and altruism: A qualitative investigation of "drug checkers" in North America.
    Palamar JJ; Acosta P; Sutherland R; Shedlin MG; Barratt MJ
    Int J Drug Policy; 2019 Dec; 74():160-169. PubMed ID: 31610451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A qualitative assessment of key considerations for drug checking service implementation.
    Grace Rose C; Pickard AS; Kulbokas V; Hoferka S; Friedman K; Epstein J; Lee TA
    Harm Reduct J; 2023 Oct; 20(1):151. PubMed ID: 37848875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Qualitative and quantitative characteristics of xylazine-associated deaths detected using a post-mortem toxicology testing program.
    Vohra V; Stroh-Steiner GK; Jones P
    Clin Toxicol (Phila); 2023 Dec; 61(12):1040-1046. PubMed ID: 38088581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is needed for implementing drug checking services in the context of the overdose crisis? A qualitative study to explore perspectives of potential service users.
    Wallace B; van Roode T; Pagan F; Phillips P; Wagner H; Calder S; Aasen J; Pauly B; Hore D
    Harm Reduct J; 2020 May; 17(1):29. PubMed ID: 32398090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential impacts of community drug checking within the overdose crisis: qualitative study exploring the perspective of prospective service users.
    Wallace B; van Roode T; Pagan F; Hore D; Pauly B
    BMC Public Health; 2021 Jun; 21(1):1156. PubMed ID: 34134698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid Analysis of Drugs: A Pilot Surveillance System To Detect Changes in the Illicit Drug Supply To Guide Timely Harm Reduction Responses - Eight Syringe Services Programs, Maryland, November 2021-August 2022.
    Russell E; Sisco E; Thomson A; Lopes J; Rybak M; Burnett M; Heilman D; Appley MG; Gladden RM
    MMWR Morb Mortal Wkly Rep; 2023 Apr; 72(17):458-462. PubMed ID: 37104171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation and Uptake of the Massachusetts Drug Supply Data Stream: A Statewide Public Health-Public Safety Partnership Drug Checking Program.
    Green TC; Olson R; Jarczyk C; Erowid E; Erowid F; Thyssen S; Wightman R; Del Pozo B; Michelson L; Consigli A; Reilly B; Ruiz S
    J Public Health Manag Pract; 2022 Nov-Dec 01; 28(Suppl 6):S347-S354. PubMed ID: 36194805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting.
    Tupper KW; McCrae K; Garber I; Lysyshyn M; Wood E
    Drug Alcohol Depend; 2018 Sep; 190():242-245. PubMed ID: 30064061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Psychoactive Substances and receding COVID-19 pandemic: really going back to "normal"?
    Napoletano S; Basile G; Lo Faro AF; Negro F
    Acta Biomed; 2022 May; 93(2):e2022186. PubMed ID: 35545997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First drug-checking study at an electronic festival and fentanyl detection in the central region of Mexico.
    Cruz SL; Bencomo-Cruz M; Medina-Mora ME; Vázquez-Quiroz F; Fleiz-Bautista C
    Harm Reduct J; 2023 Dec; 20(1):174. PubMed ID: 38053148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Take-home drug checking as a novel harm reduction strategy in British Columbia, Canada.
    Klaire S; Janssen RM; Olson K; Bridgeman J; Korol EE; Chu T; Ghafari C; Sabeti S; Buxton JA; Lysyshyn M
    Int J Drug Policy; 2022 Aug; 106():103741. PubMed ID: 35671687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.